1-aminotetralin
Description
1-Aminotetralin (1-AT) is a **chemical compound** that plays a significant role in **neuroscientific research**.
Here's why it's important:
**1. Structural Similarity to Neurotransmitters:**
* 1-AT shares a similar chemical structure with dopamine, a crucial neurotransmitter involved in motivation, reward, and movement. This structural resemblance allows it to interact with dopamine receptors.
**2. Activity at Dopamine Receptors:**
* 1-AT is known to **activate dopamine receptors**, particularly the D2 subtype, which is associated with various neurological processes. This makes it a valuable tool for studying dopamine signaling in the brain.
**3. Research Applications:**
* **Parkinson's Disease:** 1-AT has been investigated as a potential treatment for Parkinson's disease, a neurodegenerative disorder characterized by dopamine depletion. It may help alleviate motor symptoms by stimulating dopamine receptors.
* **Addiction:** 1-AT's ability to influence dopamine signaling makes it relevant to addiction research. Understanding its effects on dopamine receptors could provide insights into the mechanisms of drug dependence and potential therapeutic strategies.
* **Neuropsychiatric Disorders:** 1-AT's interactions with dopamine pathways make it relevant to research on other neuropsychiatric disorders like schizophrenia and depression, where dopamine dysfunction is implicated.
**4. Pharmacological Research:**
* 1-AT serves as a **chemical probe** to study the function of dopamine receptors. Researchers can use it to understand how these receptors work at a molecular level.
* It's also used in the development of **new drugs** targeting dopamine receptors for various neurological and psychiatric conditions.
**5. Limitations:**
* 1-AT has **limited bioavailability**, meaning it doesn't easily cross the blood-brain barrier, which restricts its therapeutic potential.
* It can also cause **side effects** due to its interaction with other neurotransmitter systems.
**Overall, 1-aminotetralin's importance in research stems from its ability to interact with dopamine receptors, its potential therapeutic implications, and its utility as a tool for studying dopamine signaling in the brain.**
1-aminotetralin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 18066 |
| SCHEMBL ID | 40422 |
| SCHEMBL ID | 4667951 |
| SCHEMBL ID | 14543304 |
| MeSH ID | M0106558 |
Synonyms (82)
| Synonym |
|---|
| AC-5739 |
| nsc-30349 |
| 2217-40-5 |
| nsc30349 |
| aminotetralin [czech] |
| brn 1102357 |
| tetrahydro-beta-naphthylamine |
| beta-1,2,3,4-tetrahydronaphthylamine |
| 2-amino-1,2,3,4-tetrahydronaftalen [czech] |
| einecs 220-973-7 |
| 1,2,3,4-tetrahydro-1-naphthylamine, 97% |
| 1,2,3,4-tetrahydronaphthalen-1-amine |
| STK397313 |
| 1-aminotetralin |
| 1,2,3,4-tetrahydro-1-naphthylamine |
| 1-amino-1,2,3,4-tetrahydronaphthalene |
| T2501 |
| AKOS000113660 |
| T1992 |
| HMS1735D12 |
| 1,2,3,4-tetrahydro-naphthalen-1-ylamine |
| 1-amino-1,2,3,4-tetrahydro-naphthalene |
| unii-lgx8t83g7x |
| 4-12-00-02943 (beilstein handbook reference) |
| aminotetralin |
| A815992 |
| o7a3gv2pnx , |
| einecs 218-712-7 |
| nsc 30349 |
| ec 218-712-7 |
| unii-o7a3gv2pnx |
| 1,2,3,4-tetrahydronaphthylamine |
| BP-10652 |
| FT-0602202 |
| FT-0602203 |
| FT-0607310 |
| AM20060829 |
| AB00150 |
| AB06758 |
| AKOS016039381 |
| SCHEMBL40422 |
| 1,2,3,4-tetrahydro-1-naphtylamine |
| rac-1,2,3,4-tetrahydro-1-naphthylamine |
| 1,2,3,4-tetrahydronaphthalen-1-ylamine |
| racemic 1,2,3,4-tetrahydro-1-naphthylamine |
| racemic 1,2,3,4-tetrahydro-1-naphtylamine |
| 1,2,3,4-tetrahydro-1-naphthalenylamine |
| 1-aminotetraline |
| rac-1,2,3,4-tetrahydro-naphthalen-1-ylamine |
| 1,2,3,4-tetrahydro naphthyl amine |
| racemic 1,2,3,4-tetrahydro-l-naphthylamine |
| tetrahydro-1-naphthylamine |
| SCHEMBL4667951 |
| 1-naphthalenamine, 1,2,3,4-tetrahydro- |
| Q-100282 |
| SCHEMBL14543304 |
| 1,2,3,4-tetrahydro-1-naphthalenamine # |
| 1,2,3,4-tetrahydronaphthalene-1-amine |
| (+/-)-1-aminotetralin |
| (rs)-1,2,3,4-tetrahydro-1-naphthylamine |
| (+/-)-1,2,3,4-tetrahydro-.alpha.-naphthylamine |
| (rs)-1-aminotetralin |
| 1-aminotetralin, (+/-)- |
| 1-naphthalenamine, 1,2,3,4-tetrahydro-, (+/-)- |
| (+/-)-1,2,3,4-tetrahydro-1-naphthylamine |
| mfcd00671629 |
| mfcd00001740 |
| naphthalenamine, 1,2,3,4-tetrahydro- |
| CS-W007739 |
| F0001-0783 |
| SY001972 |
| carbamicacid,[4(s)-(hydroxymethyl)-2-cyclopenten-1-yl]-1,1-dimethylethylester,(1r-cis)- |
| SY045443 |
| s)-1-amino-1,2,3,4-tetrahydronaphthalene |
| BCP26855 |
| SB13761 |
| Q27285437 |
| DTXSID70903059 |
| SY004141 |
| AS-81177 |
| EN300-18939 |
| PD179126 |
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.39) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||